BE2016C049I2 - - Google Patents

Info

Publication number
BE2016C049I2
BE2016C049I2 BE2016C049C BE2016C049C BE2016C049I2 BE 2016C049 I2 BE2016C049 I2 BE 2016C049I2 BE 2016C049 C BE2016C049 C BE 2016C049C BE 2016C049 C BE2016C049 C BE 2016C049C BE 2016C049 I2 BE2016C049 I2 BE 2016C049I2
Authority
BE
Belgium
Prior art keywords
pharmaceutical composition
leishmaniasis
proteins
animal
prevention
Prior art date
Application number
BE2016C049C
Other languages
English (en)
Dutch (nl)
Original Assignee
Laboratorios Leti S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA2256124A external-priority patent/CA2256124C/en
Application filed by Laboratorios Leti S L filed Critical Laboratorios Leti S L
Publication of BE2016C049I2 publication Critical patent/BE2016C049I2/nl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BE2016C049C 1998-12-23 2016-10-06 BE2016C049I2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11382598P 1998-12-23 1998-12-23
CA2256124A CA2256124C (en) 1998-12-23 1998-12-23 Chimeric gene formed of the dna sequences that encode the antigenic determinants of four proteins of l. infantum, and protein encoded by said gene, and pharmaceutical composition useful for preventing and/or treating leishmaniosis in animals or humans
PCT/EP1999/010441 WO2000039298A1 (en) 1998-12-23 1999-12-23 Chimeric gene encoding the antigenic determinants of four proteins of l. infantum

Publications (1)

Publication Number Publication Date
BE2016C049I2 true BE2016C049I2 (de) 2019-03-05

Family

ID=25680668

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2016C049C BE2016C049I2 (de) 1998-12-23 2016-10-06

Country Status (22)

Country Link
EP (1) EP1141305B1 (de)
CN (1) CN1158387C (de)
AT (2) ATE429498T1 (de)
AU (1) AU759316B2 (de)
BE (1) BE2016C049I2 (de)
BG (1) BG65569B1 (de)
BR (1) BRPI9916549B8 (de)
CY (3) CY1105331T1 (de)
CZ (1) CZ20012360A3 (de)
DE (2) DE69931518T2 (de)
DK (1) DK1141305T3 (de)
ES (2) ES2326174T3 (de)
HR (1) HRP20010554A2 (de)
HU (1) HUP0104743A3 (de)
IL (2) IL143956A0 (de)
LU (1) LU93259I2 (de)
MX (1) MXPA01006548A (de)
NL (1) NL300830I2 (de)
PT (2) PT1141305E (de)
SI (1) SI1624063T1 (de)
TR (1) TR200102655T2 (de)
WO (1) WO2000039298A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613337B1 (en) * 1997-02-12 2003-09-02 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
ES2169995B1 (es) * 2000-04-17 2003-12-01 Leti Lab Composicion a base de la proteina lip2a y su uso en la preparacion de un medicamento para suscitar una respuesta inmune contra un antigeno.
US6673351B1 (en) 2001-03-16 2004-01-06 Astralis, Llc Compositions and methods for the treatment and clinical remission of psoriasis
WO2006058243A2 (en) * 2004-11-24 2006-06-01 Yale University Leishmania antigens and related compositions and uses
CA2712475A1 (en) * 2008-01-18 2009-07-23 Laboratorios Leti, S.L. Unipersonal Vaccine comprising a ribosomal protein extract (rpe) and optionally a th1-promoting adjuvant
CN102483413A (zh) * 2009-07-13 2012-05-30 热体实验室有限公司 使用核糖体蛋白提取物(rpe)的寄生虫病如利什曼病的诊断
SA110310855B1 (ar) 2009-11-13 2014-09-16 Laboratories Leti S L Unipersonal استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي
BR102019003639A2 (pt) * 2019-02-22 2021-11-16 Fundação Oswaldo Cruz Proteína quimérica, seu método para produção e uso, bem como molécula de ácido nucleico, cassete de expressão, vetor de expressão, célula hospedeira, composição para diagnóstico de leishmaniose, kit de diagnóstico de leishmaniose e método de diagnóstico de leishmaniose in vitro
ES2795149B2 (es) 2020-06-08 2022-07-04 Univ Madrid Complutense Quimera sintetica multiepitopica como vacuna y tratamiento frente a leishmaniosis en mamiferos
CN112662694A (zh) * 2020-12-25 2021-04-16 康九生物科技(长春)有限公司 一种麦芽糖结合蛋白、麦芽糖结合蛋白表达载体、重组工程菌及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0703295A1 (de) * 1994-09-26 1996-03-27 Institut Pasteur GP63-Fusionsprotein exprimierendes, rekombinantes, BCG enthaltende Impfstoffzusammensetzung
US5912166A (en) * 1995-04-21 1999-06-15 Corixa Corporation Compounds and methods for diagnosis of leishmaniasis
ES2133236B1 (es) * 1997-06-27 2000-04-16 Leti Lab Gen quimerico formado por las secuencias de dna que codifican los determinantes antigenicos de cuatro proteinas de l. infantum, aplicable para el diagnostico serologico de leishmaniosis canina y proteina obtenida.

Also Published As

Publication number Publication date
BRPI9916549B8 (pt) 2022-08-30
LU93259I2 (fr) 2016-12-06
BR9916549A (pt) 2005-01-04
PT1141305E (pt) 2006-10-31
CY1109221T1 (el) 2014-07-02
DE69940793D1 (de) 2009-06-04
BG65569B1 (bg) 2008-12-30
DK1141305T3 (da) 2006-09-25
ATE327332T1 (de) 2006-06-15
EP1141305B1 (de) 2006-05-24
CN1335889A (zh) 2002-02-13
ATE429498T1 (de) 2009-05-15
HUP0104743A2 (hu) 2002-03-28
IL143956A (en) 2010-11-30
ES2273519T3 (es) 2007-05-01
HRP20010554A2 (en) 2002-08-31
MXPA01006548A (es) 2003-03-27
WO2000039298A1 (en) 2000-07-06
EP1141305A1 (de) 2001-10-10
HUP0104743A3 (en) 2004-10-28
DE69931518D1 (de) 2006-06-29
NL300830I1 (nl) 2016-09-28
CY1105331T1 (el) 2010-03-03
PT1624063E (pt) 2009-06-19
CY2016033I2 (el) 2017-03-15
TR200102655T2 (tr) 2002-04-22
CN1158387C (zh) 2004-07-21
BG105725A (en) 2002-06-28
CZ20012360A3 (cs) 2001-10-17
CY2016033I1 (el) 2017-03-15
ES2326174T3 (es) 2009-10-02
IL143956A0 (en) 2002-04-21
AU2434200A (en) 2000-07-31
DE69931518T2 (de) 2006-12-21
SI1624063T1 (sl) 2009-08-31
AU759316B2 (en) 2003-04-10
NL300830I2 (nl) 2020-08-31
BRPI9916549B1 (pt) 2018-10-02

Similar Documents

Publication Publication Date Title
BE2016C049I2 (de)
WO2000053758A3 (en) Compositions and methods for the treatment of immune related diseases
WO2000073452A3 (en) Compositions and methods for the treatment of immune related diseases
PT2009025E (pt) Método de inibição da actividade dos osteoclastos
IL92937A0 (en) Human derived monocyte attracting protein,pharmaceutical compositions comprising it and dna encoding it
MXPA02010458A (es) Peptido modulador del receptor de trombopoyetina.
AU4011300A (en) Compositions and methods for the treatment of immune related diseases
WO1999014241A3 (en) Compositions and methods for the treatment of immune related diseases
MXPA04001986A (es) Composiciones y metodos para el tratamiento de enfermedades relacionadas a la inmunidad.
ATE310828T1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
YU51601A (sh) Himerni gen koji kodira antigene determinante četiri proteina l.infantum
WO2001095946A3 (en) Combination product for carrying out a cytotoxic treatment in a mammal
WO2001040465A3 (en) Compositions and methods for the treatment of immune related diseases
PL336897A1 (en) Novel salts of bpc peptides, pharmaceutic compositions conatining them and method of obtaining such salts
DE59410423D1 (de) Serin-threonin-kinase enthaltendes mittel zur tumortherapie und tumordiagnose
WO2000015797A3 (en) Compositions and methods for the treatment of immune related diseases
WO2001066740A3 (en) Compositions and methods for the treatment of immune related diseases
WO2001016319A3 (en) Compositions and methods for the treatment of immune related diseases
ATE213637T1 (de) Bismut enthaltende zusammensetzungen zur verhütung und behandlung gastrointestinaler beschwerden
ATE480560T1 (de) Zusammensetzung zur behandlung von periodontalen erkrankungen
EP1624063A3 (de) Chimärisches Gen, dass für die antigenischen Determinanten von vier Proteinen aus L. Infantum kodiert
MX9800686A (es) Nueva proteina hmw humana mp52s.
EP1529842A3 (de) Zusammenstzung und Verfahren zur Behandlung von immunverwandten Krankheiten